Talzenna - opinion on variation to marketing authorisation
Opinion
EMA has issued an opinion on a change to this medicine's authorisation
talazoparib
Post-authorisationHuman
Opinion
On 12 November 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Talzenna. The marketing authorisation holder for this medicinal product is Pfizer Europe MA EEIG.
The CHMP adopted a new indication, as follows:
HRRm metastatic hormone-sensitive prostate cancer
Talzenna is indicated in combination with enzalutamide and androgen deprivation therapy (ADT) for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic hormone-sensitive prostate cancer (mHSPC) (for biomarker-based patient selection see section 4.2).
For information, the full indications for Talzenna will be as follows:
Breast cancer
Talzenna is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2‑mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments (see section 5.1). Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy.
Prostate cancer
Metastatic castration-resistant prostate cancer
Talzenna is indicated in combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.
HRRm metastatic hormone-sensitive prostate cancer
Talzenna is indicated in combination with enzalutamide and androgen deprivation therapy (ADT) for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic hormone-sensitive prostate cancer (mHSPC) (for biomarker-based patient selection see section 4.2).
Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.
Note: New text in bold
CHMP post-authorisation summary of positive opinion for Talzenna (VR-0000350865)